ArticlePloS one2025
Is laccase from medicinal mushroom Cerrena unicolor cytotoxic to colon cancer cell line CT-26?
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Anticancer Properties of Selected Wood-Inhabiting Fungi.Nutrients · 2026Review
- Modern Pro-Health Applications of Medicinal Mushrooms: Insights into theMolecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION AND
objectiveColorectal cancer takes an increasing toll every year. Despite the dynamic development of pharmacology, there is still no drug that would be strong enough to cause apoptosis of cancer cells, but at the same time would be free from numerous side effects. Taking traditional Eastern medicine into account, studies were carried out using an extract - laccase (LAC) from a medical mushroom called Cerrena unicolor- on CT-26 colon cancer cells. Preliminary cytotoxicity tests have already confirmed that the examined extract affects cancer cells and at the same time has no significant effect on L929 cells. The Electric Cell-substrate Impedance Sensing system (ECIS) and standard methods were used in this work. ECIS used in this study is an advanced in vitro impedance measuring system. MATERIALS AND
methodsThe CT-26 and L929 cells were treated by five different concentrations of the LAC preparation ranging from 0.025 to 250 μg/mL. Concentrations selected for the ECIS system assay were: 0.25;2.5 and 250 μg/mL. The default optimal frequencies in the ECIS system for Resistance (R) 4000Hz, Impedance (Z) 16000Hz, Capacitance (C) 64000Hz were used. RESLUTS: ECIS results demonstrate the potential anti-cancer activity of the laccase preparation against CT-26 cancer cells, and affect theL929 cells in to a lesser extent. Thanks to the use of the ECIS research technique, it was possible to monitor live changes in cell morphology and physiology, which translates into accurate conclusions about the action of the tested preparation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.